{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:34:57Z","timestamp":1787027697257,"version":"build-2736575974"},"reference-count":73,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Background: The objective of this study was to investigate the DRD2 rs1800497, rs1799732, rs1801028, DRD3 rs6280, and HTR2A rs6314, rs7997012, and rs6311 single-nucleotide polymorphism (SNP) correlations with resistance to second-generation antipsychotics (SGAs) in a real-world sample of patients with treatment-resistant mental disorders. Methods: We divided 129 participants into a high treatment resistance (HTR) group (current treatment with two SGAs, or clozapine, or classic neuroleptics for a failure of previous SGAs trials) and a low treatment resistance (LTR) group (current treatment with one atypical antipsychotic). We used Next-Generation Sequencing on DNA isolated from peripheral blood samples to analyze the polymorphisms. We performed logistic regression to search for predictors of HTR membership. Results: A diagnosis of schizophrenia significantly predicted the HTR membership compared to other diagnoses. Other predictors were the DRD3 rs6280 C|T (OR = 22.195) and T|T (OR = 18.47) vs. C|C, HTR2A rs7997012 A|G vs. A|A (OR = 6.859) and vs. G|G (OR = 2.879), and DRD2 rs1799732 I|I vs. D|I (OR = 12.079) genotypes. Conclusions: A diagnosis of schizophrenia and the DRD2 rs1799732, DRD3 rs6280, and HTR2A rs7997012 genotypes can predict high treatment resistance to SGAs.<\/jats:p>","DOI":"10.3390\/biomedicines11072088","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T01:27:32Z","timestamp":1690248452000},"page":"2088","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["DRD2, DRD3, and HTR2A Single-Nucleotide Polymorphisms Involvement in High Treatment Resistance to Atypical Antipsychotic Drugs"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-6944","authenticated-orcid":false,"given":"Antonio","family":"Del Casale","sequence":"first","affiliation":[{"name":"Department of Dynamic and Clinical Psychology and Health Studies, Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Unit of Psychiatry, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Simmaco","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Unit of Laboratory and Advanced Molecular Diagnostics, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8540-4407","authenticated-orcid":false,"given":"Martina Nicole","family":"Modesti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Zocchi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1477-2645","authenticated-orcid":false,"given":"Jan Francesco","family":"Arena","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Bilotta","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Alcibiade","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sarli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Cutillo","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Antonelli","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"La Spina","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3852-4585","authenticated-orcid":false,"given":"Ottavia","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Unit of Laboratory and Advanced Molecular Diagnostics, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-1087","authenticated-orcid":false,"given":"Robert","family":"Preissner","sequence":"additional","affiliation":[{"name":"Structural Bioinformatics Group, Institute for Physiology, Charit\u00e9\u2014University Medicine Berlin, 10115 Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7839-9125","authenticated-orcid":false,"given":"Marina","family":"Borro","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Unit of Laboratory and Advanced Molecular Diagnostics, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8667-3094","authenticated-orcid":false,"given":"Giovanna","family":"Gentile","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"},{"name":"Unit of Laboratory and Advanced Molecular Diagnostics, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Girardi","sequence":"additional","affiliation":[{"name":"Department of Dynamic and Clinical Psychology and Health Studies, Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1886-4977","authenticated-orcid":false,"given":"Maurizio","family":"Pompili","sequence":"additional","affiliation":[{"name":"Unit of Psychiatry, \u2018Sant\u2019Andrea\u2019 University Hospital, 00189 Rome, Italy"},{"name":"Department of Neuroscience, Mental Health and Sensory Organs (NESMOS), Faculty of Medicine and Psychology, Sapienza University of Rome, 00185 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/10401230591002002","article-title":"History of the Discovery and Clinical Introduction of Chlorpromazine","volume":"17","author":"Alamo","year":"2005","journal-title":"Ann. Clin. Psychiatry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/schbul\/sbp006","article-title":"The Dopamine Hypothesis of Schizophrenia: Version III\u2014The Final Common Pathway","volume":"35","author":"Howes","year":"2009","journal-title":"Schizophr. Bull."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2020). The American Psychiatric Association Practice Guideline for the Treatment of Patients with Schizophrenia, American Psychiatric Association Publishing.","DOI":"10.1176\/appi.books.9780890424841"},{"key":"ref_4","unstructured":"National Institute for Health and Care Excellence (NICE) (2014). Psychosis and Schizophrenia in Adults: Prevention and Management Clinical Guideline, National Institute for Health and Care Excellence."},{"key":"ref_5","unstructured":"National Institute for Health and Care Excellence (NICE) (2014). Bipolar Disorder: Assessment and Management Clinical Guideline, National Institute for Health and Care Excellence."},{"key":"ref_6","unstructured":"National Institute for Health and Care Excellence (NICE) (2022). Depression in Adults: Treatment and Management NICE Guideline, National Institute for Health and Care Excellence."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"100760","DOI":"10.1136\/gpsych-2022-100760","article-title":"Bipolar Depression: A Review of Treatment Options","volume":"35","author":"Levenberg","year":"2022","journal-title":"Gen. Psychiatr."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"710","DOI":"10.2174\/1570159X16666180813155017","article-title":"Psychopharmacological Treatment of Obsessive-Compulsive Disorder (OCD)","volume":"17","author":"Sorice","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.pnpbp.2018.08.001","article-title":"Posttraumatic Stress Disorder with Secondary Psychotic Features (PTSD-SP): Diagnostic and Treatment Challenges HHS Public Access","volume":"88","author":"Compean","year":"2019","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2016). The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients with Dementia, American Psychiatric Association.","DOI":"10.1176\/appi.books.9780890426807"},{"key":"ref_11","first-page":"151","article-title":"Systematic Review and Meta-Analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of Response","volume":"62","author":"Moreno","year":"2022","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.euroneuro.2022.11.008","article-title":"Effects of Quetiapine on Sleep: A Systematic Review and Meta-Analysis of Clinical Trials","volume":"67","author":"Lin","year":"2023","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"36608","DOI":"10.4088\/JCP.MY20096AH1C","article-title":"Treatment-Resistant Schizophrenia: Definition, Predictors, and Therapy Options","volume":"82","author":"Correll","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. First- and Second-Generation Antipsychotics in Treatment-Refractory Schizophrenia: Systematic Review and Meta-Analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41398-021-01613-2","article-title":"Efficacy and Safety of Clozapine in Psychotic Disorders\u2014A Systematic Quantitative Meta-Review","volume":"11","author":"Wagner","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_17","first-page":"117","article-title":"Treatment-Resistant Schizophrenia: Current Insights on the Pharmacogenomics of Antipsychotics","volume":"9","author":"Lally","year":"2016","journal-title":"Pharmgenomics Pers. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41386-019-0577-3","article-title":"Heterogeneity and Efficacy of Antipsychotic Treatment for Schizophrenia with or without Treatment Resistance: A Meta-Analysis","volume":"45","author":"Mizuno","year":"2020","journal-title":"Neuropsychopharmacology"},{"key":"ref_19","first-page":"1","article-title":"Is Treatment-Resistant Depression a Useful Concept?","volume":"19","author":"Malhi","year":"2016","journal-title":"BMJ Ment Health"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.euroneuro.2007.03.009","article-title":"What Is the Meaning of Treatment Resistant\/Refractory Major Depression (TRD)? A Systematic Review of Current Randomized Trials","volume":"17","author":"Berlim","year":"2007","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1111\/bph.15596","article-title":"Perspectives for Therapy of Treatment-resistant Depression","volume":"179","author":"Papp","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"ref_22","unstructured":"FDA (2023, March 20). CDER. Mccrayk Major Depressive Disorder: Developing Drugs for Treatment Guidance for Industry. Draft Guidance, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/major-depressive-disorder-developing-drugs-treatment."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1016\/S0140-6736(18)31948-2","article-title":"Depression","volume":"392","author":"Malhi","year":"2018","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1177\/0706743716659417","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 3. Pharmacological Treatments","volume":"61","author":"Kennedy","year":"2016","journal-title":"Can. J. Psychiatry"},{"key":"ref_25","unstructured":"American Psychological Association (2023, March 20). Clinical Practice Guideline for the Treatment of Depression across Three Age Cohorts. Available online: https:\/\/www.apa.org\/depression-guideline\/guideline.pdf."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.jad.2021.12.134","article-title":"Augmentation Strategies for Treatment Resistant Major Depression: A Systematic Review and Network Meta-Analysis","volume":"302","author":"Joseph","year":"2022","journal-title":"J. Affect. Disord."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Ruberto, V.L., Jha, M.K., and Murrough, J.W. (2020). Pharmaceuticals Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals, 13.","DOI":"10.3390\/ph13060116"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1177\/02698811211013579","article-title":"Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium","volume":"35","author":"Bahji","year":"2021","journal-title":"J. Psychopharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.tips.2022.09.011","article-title":"Feature Review Pharmacogenomics in Treatment of Depression and Psychosis: An Update","volume":"43","author":"Jukic","year":"2022","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Kam, H., and Jeong, H. (2020). Pharmacogenomic Biomarkers and Their Applications in Psychiatry. Genes, 11.","DOI":"10.3390\/genes11121445"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.2217\/pgs-2021-0051","article-title":"The Pharmacogenetics of Treatment with Olanzapine","volume":"22","author":"Zubiaur","year":"2021","journal-title":"Pharmacogenomics"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Vaiman, E.E., Shnayder, N.A., Novitsky, M.A., Dobrodeeva, V.S., Goncharova, P.S., Bochanova, E.N., Sapronova, M.R., Popova, T.E., Tappakhov, A.A., and Nasyrova, R.F. (2021). Biomedicines Candidate Genes Encoding Dopamine Receptors as Predictors of the Risk of Antipsychotic-Induced Parkinsonism and Tardive Dyskinesia in Schizophrenic Patients. Biomedicines, 9.","DOI":"10.3390\/biomedicines9080879"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/bcpt.13111","article-title":"Association between Dopamine Receptor Gene Polymorphisms and Effects of Risperidone Treatment: A Systematic Review and Meta-Analysis","volume":"124","author":"Ma","year":"2019","journal-title":"Basic. Clin. Pharmacol. Toxicol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e747","DOI":"10.1038\/tp.2016.22","article-title":"Genetic Variation and Dopamine D2 Receptor Availability: A Systematic Review and Meta-Analysis of Human in Vivo Molecular Imaging Studies","volume":"6","author":"Gluskin","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/0269881112463469","article-title":"DRD2\/ANKK1 Taq1A (Rs 1800497 C>T) Genotypes Are Associated with Susceptibility to Second Generation Antipsychotic-Induced Akathisia","volume":"27","author":"Lawford","year":"2013","journal-title":"J. Psychopharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1515\/dmpt-2022-0143","article-title":"The ANKK1\/DRD2 Gene TaqIA Polymorphism (Rs1800497) Is Associated with the Severity of Extrapyramidal Side Effects of Haloperidol Treatment in CYP2D6 Extensive Metabolizers with Schizophrenia Spectrum Disorders","volume":"38","author":"Kibitov","year":"2022","journal-title":"Drug Metab. Pers. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2174\/1381612827666210215151333","article-title":"Risk Genes in Schizophrenia and Their Importance in Choosing the Appropriate Antipsychotic Treatment","volume":"27","author":"Werner","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.2147\/NDT.S148824","article-title":"Neuropsychiatric Disease and Treatment Dovepress Potential Link between Genetic Polymorphisms of Catechol-O-Methyltransferase and Dopamine Receptors and Treatment Efficacy of Risperidone on Schizophrenia","volume":"2017","author":"Han","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.euroneuro.2015.12.035","article-title":"Pharmacogenetics of Clozapine Response and Induced Weight Gain: A Comprehensive Review and Meta-Analysis","volume":"26","author":"Gressier","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/YPG.0000000000000320","article-title":"Genetic Determinants Associated with Response to Clozapine in Schizophrenia: An Umbrella Review","volume":"32","author":"Papadimitriou","year":"2022","journal-title":"Psychiatr. Genet."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"550225","DOI":"10.3389\/fpsyt.2020.550225","article-title":"Genetic Determinants of Gating Functions: Do We Get Closer to Understanding Schizophrenia Etiopathogenesis?","volume":"11","author":"Ma","year":"2020","journal-title":"Front. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamapsychiatry.2013.1378","article-title":"Converging Evidence for the Association of Functional Genetic Variation in the Serotonin Receptor 2a Gene with Prefrontal Function and Olanzapine Treatment","volume":"70","author":"Blasi","year":"2013","journal-title":"JAMA Psychiatry"},{"key":"ref_43","unstructured":"(2023, January 27). View of DRD3 Ser9Gly Polymorphism and Its Influence on Risperidone Response in Autistic Children. Available online: https:\/\/journals.library.ualberta.ca\/jpps\/index.php\/JPPS\/article\/view\/29529\/21388."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1177\/0706743717720448","article-title":"Canadian Schizophrenia Guidelines Guidelines for the Pharmacotherapy of Schizophrenia in Adults","volume":"62","author":"Remington","year":"2017","journal-title":"Can. J. Psychiatry"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders, American Psychiatric Association Publishing. [5th ed.].","DOI":"10.1176\/appi.books.9780890425596"},{"key":"ref_46","unstructured":"World Health Organization (1994). International Classification of Diseases and Related Health Problems."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwn359","article-title":"Hardy-Weinberg Equilibrium Testing of Biological Ascertainment for Mendelian Randomization Studies","volume":"169","author":"Rodriguez","year":"2009","journal-title":"Am. J. Epidemiol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.pnpbp.2013.05.011","article-title":"Pharmacogenetics in Major Depression: A Comprehensive Meta-Analysis","volume":"45","author":"Niitsu","year":"2013","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajmg.b.32281","article-title":"Association between DRD2 (Rs1799732 and Rs1801028) and ANKK1 (Rs1800497) Polymorphisms and Schizophrenia: A Meta-Analysis","volume":"168B","author":"Yao","year":"2015","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"113470","DOI":"10.1016\/j.psychres.2020.113470","article-title":"Association of the Genetic Polymorphisms of Metabolizing Enzymes, Transporters, Target Receptors and Their Interactions with Treatment Response to Olanzapine in Chinese Han Schizophrenia Patients","volume":"293","author":"Yan","year":"2020","journal-title":"Psychiatry Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Oishi, K., Kanahara, N., Takase, M., Oda, Y., Nakata, Y., Niitsu, T., Ishikawa, M., Sato, Y., and Iyo, M. (2018). Vulnerable Combinations of Functional Dopaminergic Polymorphisms to Late-Onset Treatment Resistant Schizophrenia. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207133"},{"key":"ref_52","first-page":"127","article-title":"Genetic Polymorphisms in Dopaminergic System and Treatment-Resistant Schizophrenia","volume":"28","author":"Kastelic","year":"2016","journal-title":"Psychiatr. Danub."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12041-021-01306-1","article-title":"Investigating the Association between Common DRD2\/ANKK1 Genetic Polymorphisms and Schizophrenia: A Meta-Analysis","volume":"100","author":"Habibzadeh","year":"2021","journal-title":"J. Genet."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41588-022-01034-x","article-title":"Exome Sequencing in Bipolar Disorder Identifies AKAP11 as a Risk Gene Shared with Schizophrenia","volume":"54","author":"Palmer","year":"2022","journal-title":"Nat. Genet."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nature25758","article-title":"Structure of the D2 Dopamine Receptor Bound to the Atypical Antipsychotic Drug Risperidone","volume":"555","author":"Wang","year":"2018","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.psychres.2011.09.024","article-title":"A DRD2 and ANKK1 Haplotype Is Associated with Nicotine Dependence","volume":"196","author":"Voisey","year":"2012","journal-title":"Psychiatry Res."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Prasad, P., Ambekar, A., and Vaswani, M. (2010). Dopamine D2 Receptor Polymorphisms and Susceptibility to Alcohol Dependence in Indian Males: A Preliminary Study. BMC Med. Genet., 11.","DOI":"10.1186\/1471-2350-11-24"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1002\/ijc.24079","article-title":"Dopamine D2 Receptor Polymorphisms and Adenoma Recurrence in the Polyp Prevention Trial","volume":"124","author":"Murphy","year":"2009","journal-title":"Int. J. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/FPC.0b013e32833ca24b","article-title":"DRD2 Promoter Region Variation Predicts Antipsychotic-Induced Weight Gain in First Episode Schizophrenia","volume":"20","author":"Lencz","year":"2010","journal-title":"Pharmacogenet Genom."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Niewczas, M., Grzywacz, A., Le\u017anicka, K., Chmielowiec, K., Chmielowiec, J., Maciejewska-Skrendo, A., Ruzbarsky, P., Masiak, J., Czarny, W., and Ci\u0119szczyk, P. (2021). Association between Polymorphism Rs1799732 of DRD2 Dopamine Receptor Gene and Personality Traits among MMA Athletes. Genes, 12.","DOI":"10.3390\/genes12081217"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3897\/folmed.63.e61484","article-title":"Exploring Pharmacogenetic Variation in a Bulgarian Psychiatric Cohort","volume":"63","author":"Ivanov","year":"2021","journal-title":"Folia Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10571-014-0038-9","article-title":"Potential Contribution of Dopaminergic Gene Variants in ADHD Core Traits and Co-Morbidity: A Study on Eastern Indian Probands","volume":"34","author":"Maitra","year":"2014","journal-title":"Cell. Mol. Neurobiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/ajmg.b.31203","article-title":"Converging Evidence Implicates the Dopamine D3 Receptor Gene in Vulnerability to Schizophrenia","volume":"156B","author":"Zhang","year":"2011","journal-title":"Am. J. Med. Genet. B Neuropsychiatr. Genet."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1002\/hup.930","article-title":"Dopamine Receptor D3 Genotype Association with Greater Acute Positive Symptom Remission with Olanzapine Therapy in Predominately Caucasian Patients with Chronic Schizophrenia or Schizoaffective Disorder","volume":"23","author":"Adams","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"g1173","DOI":"10.1136\/bmj.g1173","article-title":"Management of Psychosis and Schizophrenia in Adults: Summary of Updated NICE Guidance","volume":"348","author":"Kuipers","year":"2014","journal-title":"BMJ"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1006\/bbrc.1996.1296","article-title":"Proposed Schizophrenia-Related Gene Polymorphism: Expression of the Ser9Gly Mutant Human Dopamine D3 Receptor with the Semliki Forest Virus System","volume":"225","author":"Lundstrom","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.schres.2019.11.058","article-title":"Effects of the 5-HT2A and DRD3 Genotypes on Cortical Morphology and Functional Connectivity Density in Drug-Na\u00efve First Episode Schizophrenia","volume":"216","author":"Kang","year":"2020","journal-title":"Schizophr. Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.euroneuro.2009.08.006","article-title":"HTR2A Gene Variation Is Involved in Antidepressant Treatment Response","volume":"20","author":"Lucae","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/npp.2009.180","article-title":"Polymorphisms in GRIK4, HTR2A, and FKBP5 Show Interactive Effects in Predicting Remission to Antidepressant Treatment","volume":"35","author":"Horstmann","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1086\/503820","article-title":"Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant Treatment","volume":"78","author":"McMahon","year":"2006","journal-title":"Am. J. Hum. Genet."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.2174\/1381612821666150605111236","article-title":"Atypical Antipsychotics and Inverse Agonism at 5-HT2 Receptors","volume":"21","author":"Sullivan","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1017\/S1461145709991027","article-title":"Genetic Variation in HTR2A Influences Serotonin Transporter Binding Potential as Measured Using PET and [11C]DASB","volume":"13","author":"Laje","year":"2010","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1179\/1743132812Y.0000000111","article-title":"Meta-Analysis of Association between the -1438A\/G (Rs6311) Polymorphism of the Serotonin 2A Receptor Gene and Major Depressive Disorder","volume":"35","author":"Jin","year":"2013","journal-title":"Neurol. Res."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/2088\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:18:14Z","timestamp":1760127494000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/11\/7\/2088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":73,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["biomedicines11072088"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines11072088","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]}}}